Fingerprint
Dive into the research topics of 'Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, William G. Wierda
Research output: Contribution to journal › Article › peer-review
2
Scopus
citations